Contraindications : התוויות נגד

4.3     Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Atomoxetine should not be used in combination with monoamine oxidase inhibitors (MAOI).
Atomoxetine should not be used within a minimum of 2 weeks after discontinuing therapy with MAOI. Treatment with MAOI should not be initiated within 2 weeks after discontinuing atomoxetine.

Atomoxetine should not be used in patients with narrow angle glaucoma, as in clinical trials the use of atomoxetine was associated with an increased incidence of mydriasis.

Atomoxetine should not be used in patients with severe cardiovascular or cerebrovascular disorders (see section 4.4 Special Warnings and Special Precautions for Use – Cardiovascular Effects). Severe cardiovascular disorders may include severe hypertension, heart failure, arterial occlusive disease, angina, haemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening arrhythmias and channelopathies (disorders caused by the dysfunction of ion channels). Severe cerebrovascular disorders may include cerebral aneurysm or stroke.

Atomoxetine should not be used in patients with pheochromocytoma or a history of pheochromocytoma (see section 4.4 Special Warnings and Special Precautions for Use – Cardiovascular Effects).